ZILBRYSQ DIN 02549247
Status: Marketed
Holder: UCB CANADA INC
Health Canada record
| Active ingredient(s) | ZILUCOPLAN (ZILUCOPLAN SODIUM) 32.4 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AJ06 ZILUCOPLAN |
|---|
| Original market date | 17-Mar-2025 |
|---|
| Current status date | 17-Mar-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
UCB Canada Inc — licence 101597, currently licensed, last inspection rating C (2024-11-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ZILUCOPLAN (ZILUCOPLAN SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02549220 | ZILBRYSQ | UCB CANADA INC | Solution | ZILUCOPLAN (ZILUCOPLAN SODIUM) 16.6 MG | Marketed |
| 02549239 | ZILBRYSQ | UCB CANADA INC | Solution | ZILUCOPLAN (ZILUCOPLAN SODIUM) 23 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 33622 | 2024-07-11 | New Drug Submission (NDS) | |
Request a quote for ZILBRYSQ
How to read a Canadian DIN record